Caladrius Biosciences to Present at the BIO International Convention 2022
Caladrius Biosciences (Nasdaq: CLBS) announced that Dr. David J. Mazzo, its CEO, will present a corporate overview at the BIO International Convention in San Diego, CA, from June 13-16, 2022. Dr. Mazzo's presentation is scheduled for June 15, 2022, at 2:15 p.m. PDT in Theatre 3. The company is focused on developing innovative therapies, including its product candidates like XOWNA® for coronary microvascular dysfunction and CLBS12 for critical limb ischemia. Caladrius recently signed a merger agreement with Cend Therapeutics, expected to close in Q3 2022.
- None.
- None.
BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.
Dr. Mazzo’s presentation will be delivered in-person on Wednesday, June 15, 2022, at 2:15 p.m. (Pacific Time) in Theatre 3. For more information about the convention and how to register, please click here.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. We are and have been developing first-in-class autologous cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include: XOWNA® (CLBS16), the subject of both a recently completed positive Phase 2a study and an ongoing Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan), recipient of a SAKIGAKE designation in Japan and eligible for early conditional approval for the treatment of critical limb ischemia (“CLI”) and Buerger’s disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (“DKD”). No assurance can be given with respect to the future of these programs. For more information on the Company, please visit www.caladrius.com.
The Company recently announced that it has signed a definitive merger agreement with Cend Therapeutics, Inc. (www.cendrx.com). The merger is expected to close in the third quarter of 2022.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com
FAQ
What is the date and time of the Caladrius presentation at the BIO International Convention?
Where is the BIO International Convention being held?
What is Caladrius Biosciences' stock symbol?
What are the key product candidates of Caladrius Biosciences?
When is the merger between Caladrius Biosciences and Cend Therapeutics expected to close?
